Welcome to our dedicated page for Eyepoint Pharmac news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on Eyepoint Pharmac stock.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical innovator advancing sustained-release therapies for retinal diseases through its proprietary Durasert E technology. This page provides investors and industry professionals with a comprehensive repository of official company news, including press releases, clinical trial updates, and strategic developments.
Access timely updates on EYPT’s progress in ocular drug delivery, including regulatory milestones, partnership announcements, and pipeline advancements. Our curated collection ensures you stay informed about critical developments in treatments for wet AMD, diabetic macular edema, and other retinal conditions.
Key updates include progress on DURAVYU™ clinical trials, licensing agreements, financial disclosures, and scientific innovations. All content is sourced directly from company communications to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to EyePoint’s latest developments. Check back regularly for authoritative updates on one of ophthalmology’s most promising sustained-release therapy developers.
EyePoint Pharmaceuticals announced positive 12-month results from the Phase 1 DAVIO clinical trial for EYP-1901, an anti-VEGF therapy aimed at treating wet AMD. The data revealed no ocular serious adverse events and stable visual acuity with a 35% rate of patients remaining supplement-free at 12 months. The company plans to initiate the Phase 2 trial (DAVIO2) in Q3 2022, targeting approximately 150 previously treated wet AMD patients. EYP-1901 shows promise for long-term maintenance therapy, with significant treatment burden reduction of 74% at 12 months.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will host an Investor Day on July 18, 2022, from 8:00 a.m. to 11:00 a.m. ET. The event will feature commentary from the management team and guest speakers Carl Regillo, M.D., and Charles Wykoff, M.D., discussing the Durasert® drug delivery platform and the Phase 2 plans for EYP-1901, aimed at treating wet AMD. A live webcast will be available, with an archived replay accessible for 90 days post-event on the company's website.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has appointed Karen Zaderej to its Board of Directors, bringing over 35 years of experience in biopharmaceuticals and medical devices. Zaderej is currently the President and CEO of AxoGen. Her expertise is expected to enhance EyePoint's strategic goals, particularly in advancing EYP-1901 for treating wet age-related macular degeneration (AMD). The investigational product utilizes EyePoint's proprietary Durasert technology, showing promising clinical data with 53% and 41% of treated eyes not requiring anti-VEGF injections up to six and nine months post-treatment.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the election of Dr. Anthony Adamis to its Board of Directors. Dr. Adamis, an accomplished ophthalmology executive with over 30 years in the biopharmaceutical industry, brings substantial experience in developing anti-VEGF drugs for eye diseases. His prior roles include Senior VP at Genentech/Roche and co-founder of EyeTech Pharmaceuticals. EyePoint aims to enhance its clinical trials for EYP-1901, a sustained delivery treatment for wet age-related macular degeneration. Phase 2 trials are expected in Q3 2022 and 2H 2022.
EyePoint Pharmaceuticals (NASDAQ: EYPT) and OcuMension Therapeutics have announced the approval of YUTIQ® in China for treating chronic non-infectious uveitis affecting the posterior segment of the eye. This approval makes YUTIQ the first drug authorized for commercialization in China based on real-world data. YUTIQ, which offers up to three years of continuous treatment, was previously approved by the FDA in 2018. The collaboration aims to enhance patient care in China, where approximately 1.4 million patients are affected by this condition.
On June 15, 2022, EyePoint Pharmaceuticals (NASDAQ: EYPT) granted stock options to nine new employees as part of their inducement awards outside the 2016 Long-Term Incentive Plan, aligning with NASDAQ Listing Rule 5635(c)(4). The total granted options amounted to 55,500 shares, with an exercise price of $7.93 per share, equal to the stock's closing price on the grant date. The options have a ten-year validity and vest over four years, contingent upon continued service with the company.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that a late-breaking abstract on the 12-month data from the Phase 1 DAVIO clinical trial for EYP-1901, aimed at treating wet age-related macular degeneration (wet AMD), will be presented at the ASRS 2022 Annual Meeting from July 13-16. The trial involved 17 patients and EYP-1901 showed promising interim safety and efficacy results, with no significant adverse effects reported. Phase 2 trials for wet AMD and diabetic retinopathy are set for Q3 and 2H 2022, respectively.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that CEO Nancy Lurker will present at the H.C Wainwright Global Healthcare Investment Conference. The presentation will be available for on-demand viewing starting May 24, 2022, at 9:00 a.m. ET. A webcast and replay will be accessible via the Company’s website for 90 days post-event.
EyePoint Pharmaceuticals focuses on developing therapeutics for serious eye disorders, utilizing its Durasert® technology. Their pipeline includes EYP-1901, targeting wet age-related macular degeneration, and the FDA-approved YUTIQ® for chronic non-infectious uveitis.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the grant of non-statutory stock options to four new employees as inducement awards, in compliance with NASDAQ Listing Rule 5635(c)(4). On May 13, 2022, the company granted options for a total of 30,500 shares at an exercise price of $9.89 per share, the closing price on that date. These options have a ten-year term and vest over four years. EyePoint is focused on developing therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained drug delivery, including the investigational treatment EYP-1901.
EyePoint Pharmaceuticals announced significant progress in its EYP-1901 clinical trials for wet AMD and NPDR. The Phase 1 trial showed positive eight-month safety and efficacy data, with net product revenues up 32% to $9.0 million in Q1 2022. A new license agreement with Betta Pharmaceuticals expands the development territory for EYP-1901. However, operating expenses rose to $27.6 million, leading to a net loss of $21.0 million. The company retains $190.8 million in cash and investments, expected to fund operations into 2024.
FAQ
What is the current stock price of Eyepoint Pharmac (EYPT)?
What is the market cap of Eyepoint Pharmac (EYPT)?
